Browsing Tag
Pfizer Inc.
26 posts
Novartis India (NSE: NOVARTIND) pays Rs 1,250cr for Pfizer’s Minipress brands
Novartis India has acquired the Indian Minipress and Minipres trademarks and related intellectual property from Pfizer for approximately ₹1,250 crore, paying about 5.5 times the brand's reported annual sales as its new ownership begins reshaping the listed pharmaceutical company.
Novartis India buys Pfizer’s Minipress for Rs 1,250cr. Why is the price so large?
Novartis India has agreed to acquire Pfizer’s Minipress and Minipres trademarks and related Indian intellectual property for about ₹1,250 crore, making a transformative portfolio bet barely six weeks after Novartis AG exited control of the listed company.
Roivant’s LISRAYA wins FDA approval as $26bn biotech enters commercial autoimmune era
Roivant has secured FDA approval for LISRAYA in adults with dermatomyositis, converting brepocitinib into a commercial product while retaining multiple late-stage opportunities in other autoimmune diseases.
Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why
Scancell’s Neuphoria Therapeutics merger unlocks Nasdaq access and up to $89 million, but dilution and debt reshape the iSCIB1+ outlook.
IP Group (LSE: IPO) rejects Railpen proposal worth up to 82.6p as valuation clash deepens
IP Group has rejected Railpen’s revised proposal despite a potential maximum value of 82.6 pence per share, arguing that the structure undervalues its portfolio and gives the proposed pension-fund consortium most of the future upside from Pfizer’s obesity-drug programmes.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
Intel and NVIDIA still lead—but here’s what’s driving volume in lesser-known small caps
Find out which U.S. stocks led January 27 trading by volume, and what the price action says about investor sentiment and sector trends today.
GSK reshapes ViiV Healthcare ownership as Shionogi replaces Pfizer with $2.1bn investment
Pfizer exits ViiV Healthcare as Shionogi boosts its stake to 21.7%. Find out how GSK is reshaping HIV strategy with a streamlined ownership structure.
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.